Union Ministers Dr Mansukh Mandaviya and Jitendra Singh launched inCOVACC, the Indian nasal vaccine today on the occasion of the…
iNCOVACC: Bharat Biotech in December 2022, got the approval for the primary 2-dose schedule, and as a heterologous booster dose
The Centre on Tuesday approved the cost of Bharat Biotech's nasal COVID-19 vaccine iNCOVACC, which will be used as a…
Those who have taken Covishield and Covaxin can take the nasal vaccine as a heterologous booster dose.
Hyderabad-based Bharat Biotech on Saturday concluded a final analysis for its vaccine Covaxin efficacy from phase-3 clinical trial claiming it…
Bharat Biotech's Covaxin has shown 77.8 per cent efficacy after the Subject Expert Committee (SEC) under the drug regulator reviewed…
An Indian Council of Medical Research (ICMR) study on Covaxin shows a comparable neutralization activity of the vaccinated individuals against…
Bharat Biotech, which has received a government purchase order for supply of 55 lakh doses of Covaxin, a COVID-19 vaccine,…
After a participant who allegedly died days after volunteering for Covaxin trial in Bhopal, Bharat Biotech on Saturday clarified that…
Covaxin, the indigenous vaccine developed by Bharat Biotech against COVID-19 in collaboration with ICMR, is 200 percent safe, company’s Chairman…